Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals at Jefferies 2019 Global Healthcare Conference  (Replay)
    Thursday, June 06, 2019 10:30 am EDT
Toggle Summary Spring Bank Announces Collaborative Research Agreement with University of Texas Southwestern Medical School for Evaluation of STING Antagonist Compounds
HOPKINTON, Mass. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into
Toggle Summary Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update
HOPKINTON, Mass. , July 31, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results for
Toggle Summary Spring Bank Announces FDA Acceptance of IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
IV-Administered SB 11285 Phase 1 Trial Planned to Initiate in Coming Weeks HOPKINTON, Mass. , July 29, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,
Toggle Summary Spring Bank Announces Dosing of Inarigivir 400mg In Multiple HBV Studies
-  First Patient Dosed Ahead of Schedule in Inarigivir 400mg CATALYST 2 Trial  -  First Patient Completes Dosing in Inarigivir 400mg Intra-Hepatic Liver Biopsy Study    -  Ongoing Inarigivir + Tenofovir Alafenamide 25mg Co-Administration Trial Expanded to Include Inarigivir 400mg Cohort HOPKINTON,
Toggle Summary Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
HOPKINTON, Mass. , July 18, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into
Toggle Summary Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors
HOPKINTON, Mass. , July 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Pamela Klein , M.D.,
Toggle Summary Spring Bank Submits IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
HOPKINTON, Mass. , July 01, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has submitted an
Toggle Summary Spring Bank to Present Pre-Clinical Data on Its Novel STING Antagonist Program at The Autoimmunity Conference
HOPKINTON, Mass. , June 27, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will present for
Toggle Summary Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
HOPKINTON, Mass. , June 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it would present
Toggle Summary Spring Bank Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
HOPKINTON, Mass. , May 28, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll ,